June 4, 2018 The addition of oxaliplatin hyperthermic peritoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with colorectal peritoneal carcinomatosis does not improve overall survival (OS) or recurrence-free survival (RFS) compared with cytoreductive surgery alone, according to the results of the phase III PRODIGE 7 trial (Abstract 3503), presented during the Gastrointestinal (Colorectal)...
Pro zobrazení tohoto obsahu je třeba být přihlášen.